Sanofi Collaborates with Blackstone to Advance Sarclisa (isatuximab) for the Treatment of Multiple Myeloma
Shots:
- The companies collaborated to invest ~$330.06M to accelerate the clinical development program for SC formulation of Sarclisa to treat patients with MM. The study is expected to be initiated in H2’22 while BXLS will be eligible to receive royalties on future SC sales
- Sanofi will be responsible to manage the clinical program and hold the full rights along with control of Sarclisa (isatuximab). The therapy has received regulatory approval for IV administration to treat patients with relapsed MM and is under review for other hematologic malignancies and solid tumors
- Sanofi collaborated with the drug delivery technology innovator to advance the development of Sarclisa SC formulation
Ref: Globe Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
